ANTIFUNGAL TREATMENT: A NEW APPROACH TO ASTHMA CARE
Journal of Clinical Immunology and Allergy is a world class open access journal intended to publish the cutting-edge research in the field of Immunology and Allergy.
Journal of Clinical Immunology and Allergy endeavours to publish both basic, fundamental and advanced developmental research in Allergy and immunology involves the management of disorders related to the immune system. These conditions range from the very common to the very rare, spanning all ages and encompassing various organ systems.
Sensitization to fungi is an important risk factor in patients with allergic respiratory tract diseases, like asthma, because it plays a major role in the development, persistence and severity of lower airway disease. While the human lung is not sterile from a fungal perspective, excess mucus and airway architecture distortion invites fungal germination which can interrupt regular immune system responses or spark an inflammatory reaction.
Current data on the effectiveness of antifungal therapy in asthma and chronic sinusitis is limited but there is indication that antifungals are effective in treating severe asthmatics – specifically for patients with allergic bronchopulmonary aspergillosis (ABPA) and severe asthma with fungal sensitization (SAFS)
Many reported less sputum production (31/62 or 50%), improved breathing (24/62 or 38.7%), less cough (20/62 or 32.2%) and less frequent rescue inhaler use (9/62 or 14.5%). Only a portion (9) of patients demonstrated true fungal sensitization or allergy via scratch test or radioallergosorbent testing.
Journal accepts original manuscripts in the form of research articles, review articles, Clinical reviews, commentaries, case reports, perspectives and short communications encompassing all aspects of Clinical Immunology and Allergy for publication in open access platform.
All the manuscript published by Clinical Immunology and Allergy are available freely online immediately after publication without any subscription charges or registration.
• After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
• A 21-day window time frame is allotted for peer-review process wherein multiple experts are contacted.
• Author proof is generated within 7 working days after the acceptance decision.
Manuscripts can be submitted at: http://www.imedpub.com/submissions/insights-allergy-asthma-bronchitis.html or can be submitted as an attachment to this E-mail: email@example.com
Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.
Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.
Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.
Clinical Immunology and Allergy